Scholars Central

Conference abstractPublished 20 Apr 2018

The hollow fiber infection model: Principles and practice

Authors: John James Stewart Cadwell

FiberCell Systems Inc, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Emerging antibiotic resistance presents a serious global health threat. Two million people in the United States were infected with antibiotic resistant bacteria in 2014 and more than 20,000 died as a direct result of these infections, many more from complications. Antimicrobial resistance has been identified as one of the three greatest threats to human health. Antibiotic discovery and development require static susceptibility testing to screen compounds, in vitro pharmacodynamics/ pharmacokinetic (PK/PD) studies to model drug dynamics and efficacy, and testing in animal models to provide critical information prior to the clinical evaluation of new antibiotics. The one compartment PK/PD model typically consists of an open central reservoir containing the organism of interest, a source of diluent and a waste reservoir. The disadvantage of this system includes: 1) Open system, not bio safe; 2) Bacteria numbers change over time; 3) Large volume requires large amount of drug and diluent; 4) Rapid changes in drug concentration not possible and cannot model short half-lives. Animal models have many shortcomings though they have served as a primary development tool for many years: It includes: 1) PK/ PD may not match human values; 2) Cannot sample same animal over time; 3)Difficult to study large numbers of bacteria to reveal resistance; 4) Many infections cannot be modeled in a mouse or other animal. To address these shortcomings, the two-compartment in vitro pharmacokinetic model utilizing hollow fiber bioreactors was developed, the Hollow fiber infection model (HFIM). The advantages of the HFIM are as follows: 1) Closed, bio-safe system; 2) Large number of organism can be tested, revealing resistance; 3) Precisely simulates human PK/PD; 4) Repetitive sampling over time, both drug and organism; 5) Total kill can be determined; 6) Single use, disposable, reproducible; 7) Two drug models can be tested; 8) Can model both dosing curve and elimination curve; 9) Can look at bacteria in different growth phases and in combination with cells. The clinical utility of the HFIM has been demonstrated and is now endorsed by the EMA. An overview of historic PK/PD models is presented and the utility of the system as it relates to antibiotics and other drugs are discussed.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Antivirals & Antiretrovirals.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Antivirals & Antiretrovirals
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “John James Stewart Cadwell”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels